PAB.AU · Patrys Limited

-

Please sign in to comment on PAB.AU

1 Comment

Admin

4 years, 1 month ago

Patrys Limited is currently in a long term uptrend where the price is trading 93.3% above its 200 day moving average.

From a valuation standpoint, the stock is 296.1% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1019.8.

Patrys Limited's total revenue rose by 78.1% to $215K since the same quarter in the previous year.

Its net income has dropped by 17.2% to $-2M since the same quarter in the previous year.

Finally, its free cash flow fell by 76.3% to $-778K since the same quarter in the previous year.

Based on the above factors, Patrys Limited gets an overall score of 2/5.

Exchange	AU
CurrencyCode	AUD
Sector	Healthcare
Industry	Biotechnology
ISIN	AU000000PAB9

Market Cap	4M
PE Ratio	None
Target Price	0.12
Beta	0.39
Dividend Yield	None

ABOUT

Patrys Limited

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. The company dvelops Deoxymab 3E10 also called PAT-DX1 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents such as radiation and many chemotherapy drugs. In addition, it develops PAT-DX3, a full-sized antibody that has DNA-targeting properties of PAT-DX1, but different pharmaceutic properties, such as tissue distribution, pharmacokinetic profile, etc. Further, it is involved in DNA targeting, blood-brain barrier, Inhibit NETosis human therapeutic applications. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.

PAB.AU · Patrys Limited

-

Patrys Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Patrys Limited using a moving average strategy